Leading Justice is a full-service marketing company working with law firms on a cash-buy basis to sign up fully-qualified, fraud-free Yaz and Yasmin cases. Here at Leading Justice, we can custom-tailor your firm’s Yaz advertising needs and help you sign up cases via internal cash buys. Our clients simply pay an agency fee to cover the cost of Yaz advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that isn’t eligible for the target campaign is reviewed to find out whether it qualifies for another type of claim. By using advanced approaches to target contacts specifically related to potential Yaz and Yasmin side effects, like blood clots and stroke, Leading Justice will increase your firm’s Yaz case load. If you are interested in helping victims of complications allegedly associated with Yaz and Yasmin oral contraceptives, our extensive consumer reach and direct advertising strategies give you the confidence and competitive edge you need to allocate your full budget, knowing that your money is being used the best way possible.
Each law firm we work with at Leading Justice plays an important role in how we classify claims as qualified or not. And while our experience working alongside plaintiff law firms enables us to know what a great case looks like, we will customize our Yaz case intake specifications to the exact criteria you are seeking. So, if your firm has certain Yaz and Yasmin qualifying case criteria that you would like us to use, we will train our intake specialists to apply the criteria to each phone call and email they receive. By eliminating the middle man, Leading Justice offer clients an opportunity for internal cash buys of Yaz and Yasmin data with zero chance of fraud.
Our Take on Yaz Birth Control Litigation
Yaz is a widely-used form of birth control introduced in the United States by Bayer and heavily marketed to women worldwide as a safe and effective form of pregnancy prevention. Both Yaz and its sister medication Yasmin belong to a small group of oral contraceptives called “fourth-generation” combination birth control pills, which means they contain both estrogen and a newer synthetic form of progestin called drospirenone. Despite the popularity of Yaz and Yasmin, serious concerns have been raised about the safety of the oral contraceptives, and statistics show that thousands of injuries and as many as 100 deaths have already been linked to the birth control medications.
Estimates indicate that 100 million women worldwide use oral contraceptives like Yaz and Yasmin as their preferred method of birth control. Unfortunately, according to a study published in the British Medical Journal, women who take drospirenone-containing oral contraceptives may be 6.3 times more likely to develop dangerous blood clots, putting them at risk of life-threatening complications like deep vein thrombosis (DVT), pulmonary embolism (PE), heart attack and stroke. As of July 2013, Bayer had already settled more than 6,000 Yaz birth control lawsuits for a total of $1.4 billion, with thousands more cases pending in state and federal courts nationwide.